Danshi Li

4.3k total citations · 2 hit papers
31 papers, 3.1k citations indexed

About

Danshi Li is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Genetics. According to data from OpenAlex, Danshi Li has authored 31 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cardiology and Cardiovascular Medicine, 9 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Danshi Li's work include Cardiac electrophysiology and arrhythmias (16 papers), Atrial Fibrillation Management and Outcomes (12 papers) and Cardiac Arrhythmias and Treatments (10 papers). Danshi Li is often cited by papers focused on Cardiac electrophysiology and arrhythmias (16 papers), Atrial Fibrillation Management and Outcomes (12 papers) and Cardiac Arrhythmias and Treatments (10 papers). Danshi Li collaborates with scholars based in United States, Canada and Germany. Danshi Li's co-authors include Stanley Nattel, Tack Ki Leung, Samir Fareh, Zhiguo Wang, Kaori Shinagawa, Sophie Cardin, Li Pang, Alvin Shrier, Kevin Petrecca and Peter Melnyk and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Circulation Research.

In The Last Decade

Danshi Li

30 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Promotion of Atrial Fibrillation by Heart Failure in Dogs

1999 1.1k citations Danshi Li, Stanley Nattel et al. profile →
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure

2001 535 citations Danshi Li, Zhiguo Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danshi Li United States	20	2.6k	663	181	159	127	31	3.1k
Bruce S. Stambler United States	33	3.5k 1.3×	572 0.9×	132 0.7×	344 2.2×	22 0.2×	120	4.1k
J.J.J. van Giezen Sweden	20	1.3k 0.5×	186 0.3×	139 0.8×	441 2.8×	369 2.9×	41	1.9k
Munehito Ideishi Japan	21	998 0.4×	340 0.5×	260 1.4×	127 0.8×	41 0.3×	57	1.6k
M. Urooj Zafar United States	22	754 0.3×	240 0.4×	251 1.4×	442 2.8×	206 1.6×	60	1.5k
Hiroyuki Yaoita Japan	17	574 0.2×	621 0.9×	74 0.4×	249 1.6×	122 1.0×	52	1.4k
Emanuela Morgante Italy	18	1.2k 0.5×	461 0.7×	58 0.3×	150 0.9×	28 0.2×	30	2.2k
Johannes Ruef Germany	21	416 0.2×	485 0.7×	68 0.4×	509 3.2×	187 1.5×	50	1.7k
Jan‐Arne Björkman Sweden	16	522 0.2×	240 0.4×	46 0.3×	179 1.1×	104 0.8×	38	919
S Ucchino Italy	16	340 0.1×	482 0.7×	133 0.7×	340 2.1×	106 0.8×	28	1.7k
Katsufumi Mizushige Japan	24	776 0.3×	382 0.6×	180 1.0×	314 2.0×	35 0.3×	100	1.9k

Countries citing papers authored by Danshi Li

Since Specialization

Citations

This map shows the geographic impact of Danshi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danshi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danshi Li more than expected).

Fields of papers citing papers by Danshi Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danshi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danshi Li. The network helps show where Danshi Li may publish in the future.

Co-authorship network of co-authors of Danshi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Danshi Li. A scholar is included among the top collaborators of Danshi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danshi Li. Danshi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gibson, C. Michael, Maria Cecilia Bahit, Roxana Mehran, et al.. (2025). Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). American Heart Journal. 285. 21–28. 4 indexed citations

Perera, Vidya, Joseph M. Luettgen, Ronald Aronson, et al.. (2024). Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants. Scientific Reports. 14(1). 16591–16591.

Liu, Xuejun, Jenny Jiang, Danshi Li, et al.. (2023). Antiplatelet Treatment Patterns and Outcomes for Secondary Stroke Prevention in the United Kingdom. Cardiology and Therapy. 12(4). 675–687. 2 indexed citations

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2022). Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical Pharmacokinetics. 61(6). 857–867. 25 indexed citations

Sharma, Mukul, Carlos A. Molina, Ḱazunori Toyoda, et al.. (2022). Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention. Journal of Stroke and Cerebrovascular Diseases. 31(10). 106742–106742. 32 indexed citations

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2022). Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clinical Pharmacokinetics. 61(10). 1405–1416. 13 indexed citations

Perera, Vidya, Danshi Li, Zhaoqing Wang, et al.. (2021). SINGLE-DOSE PHARMACOKINETICS OF BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) IN PARTICIPANTS WITH NORMAL RENAL FUNCTION AND PARTICIPANTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT. Journal of the American College of Cardiology. 77(18). 1839–1839. 1 indexed citations

Perera, Vidya, Zhaoqing Wang, Joseph M. Luettgen, et al.. (2021). First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clinical and Translational Science. 15(2). 330–342. 69 indexed citations

Payne, R. Mark, Kristin M. Burns, Andrew C. Glatz, et al.. (2019). A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study. American Heart Journal. 217. 52–63. 48 indexed citations

10.

Chen, Jie, Qian Zhao, Li‐Qiang Sun, et al.. (2016). Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus. Bioorganic & Medicinal Chemistry Letters. 27(3). 590–596. 5 indexed citations

11.

Mathieu, Chantal, Aurelian-Emil Ranetti, Danshi Li, et al.. (2015). A Randomized, Double-Blind, Phase 3 Trial of Dapagliflozin Add-on to Saxagliptin plus Metformin in Type 2 Diabetes. Lirias (KU Leuven). 2 indexed citations

12.

Lloyd, John, Heather J. Finlay, James A. Johnson, et al.. (2015). Pseudosaccharin amines as potent and selective KV1.5 blockers. Bioorganic & Medicinal Chemistry Letters. 25(21). 4983–4986. 5 indexed citations

13.

Mathieu, Chantal, Aurelian-Emil Ranetti, Danshi Li, et al.. (2015). Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care. 38(11). 2009–2017. 125 indexed citations

14.

Johnson, James A., Ningning Xu, Yoon Jeon, et al.. (2014). Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(14). 3018–3022. 5 indexed citations

15.

Quang, Khaï Le, Patrice Naud, Xiaoyan Qi, et al.. (2011). Role of T-type calcium channel subunits in post-myocardial infarction remodelling probed with genetically engineered mice. Cardiovascular Research. 91(3). 420–428. 16 indexed citations

16.

Lloyd, John, Heather J. Finlay, Lin Yan, et al.. (2010). Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers. Bioorganic & Medicinal Chemistry Letters. 20(4). 1436–1439. 81 indexed citations

17.

Lloyd, John, Heather J. Finlay, Karnail S. Atwal, et al.. (2009). Dihydropyrazolopyrimidines containing benzimidazoles as KV1.5 potassium channel antagonists. Bioorganic & Medicinal Chemistry Letters. 19(18). 5469–5473. 35 indexed citations

18.

Miller, Keith J., Ginger Wu, Jeffrey Varnes, et al.. (2009). Position 5.46 of the Serotonin 5-HT2A Receptor Contributes to a Species-Dependent Variation for the 5-HT2C Agonist (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: Impact on Selectivity and Toxicological Evaluation. Molecular Pharmacology. 76(6). 1211–1219. 8 indexed citations

19.

Shi, Hong, Huizhen Wang, Danshi Li, Stanley Nattel, & Zhiguo Wang. (2004). Differential Alterations of Receptor Densities of Three Muscarinic Acetylcholine Receptor Subtypes and Current Densities of the Corre-sponding K<sup>+</sup> Channels in Canine Atria with Atrial Fibrillation Induced by Experimental Congestive Heart Failure. Cellular Physiology and Biochemistry. 14(1-2). 31–40. 39 indexed citations

20.

Derakhchan, Katayoun, Danshi Li, Marc Courtemanche, et al.. (2001). Method for Simultaneous Epicardial and Endocardial Mapping of In Vivo Canine Heart: Application to Atrial Conduction Properties and Arrhythmia Mechanisms. Journal of Cardiovascular Electrophysiology. 12(5). 548–555. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact